A phase1/2 clinical trial of GTB-3550 (CD16/IL-15/CD33) TriKE for the treatment of CD33-expressing high-risk myelodysplastic syndromes, R/R ALL, or advanced systemic mastocytosis is ongoing (NCT03214666). This evidence concerns the gene CD33 and myelodysplastic syndrome.